TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32457373

Group type: EXPERIMENTAL
Intervention: Participatory meetings (20-minute meetings once per week for six weeks)
Number of subjects: 1924

Group type: COMPARATOR
Intervention: Status quo meetings
Number of subjects: 1924
Study: 35257151

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFNα2b
Number of subjects: 0
Study: 32564634

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-dexamethasone
Number of subjects: 0
Study: 33694035

Group type: EXPERIMENTAL
Intervention: Daytime CPAP application (30-60 min)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care (first CPAP application on titration night)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Daytime CPAP application
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 246
Study: 35175357

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 202
Study: 32716500

Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 444

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 444
Study: 32676134

Group type: EXPERIMENTAL
Intervention: Acupuncture (12 sessions, 20 minutes each over 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitamin B1 (300 mg tablet) and Gabapentin (300 mg capsules, 3 per day for 4 weeks)
Number of subjects: 40
Study: 35588357

Group type: EXPERIMENTAL
Intervention: Usual care plus breathing exercises (UC + BrEX)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 193
Study: 34852103

Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Supervised Physical Exercise Intervention (SPEI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 61
Study: 36429394

Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy/counseling and nutrition education
Number of subjects: 38

Group type: COMPARATOR
Intervention: Educational material related to nutrition, HIV, and prediabetes
Number of subjects: 38
Study: 34312823

Group type: EXPERIMENTAL
Intervention: Early albumin administration (within the initial 24 perioperative hours)
Number of subjects: 735
Study: 32460840

Group type: EXPERIMENTAL
Intervention: Combined group-based stabilization and skill-training (SST) intervention added to individual treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 160
Study: 35351194

Group type: EXPERIMENTAL
Intervention: Subcutaneous tanezumab (2.5mg or 5mg every 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral NSAID (twice daily naproxen, celecoxib, or diclofenac)
Number of subjects: 0
Study: 33499864

Group type: EXPERIMENTAL
Intervention: mhealth messages and environmental cues
Number of subjects: 450

Group type: COMPARATOR
Intervention: HH facilities and supplies (Control)
Number of subjects: 450
Study: 32192742

Group type: EXPERIMENTAL
Intervention: Continuous Transverse Abdominal Plane (TAP) block with ropivacaine 0.375% 20 mL and ropivacaine 0.2%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous Transverse Abdominal Plane (TAP) block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous Epidural Analgesia with ropivacaine 0.2%
Number of subjects: 30
Study: 35999043

Group type: EXPERIMENTAL
Intervention: A‐Fio2
Number of subjects: 44

Group type: COMPARATOR
Intervention: M‐Fio2
Number of subjects: 44
Study: 34446493

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intervention materials (after 1 month wait)
Number of subjects: 500
Study: 32705504

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (30 healthy individuals)
Number of subjects: 200
Study: 32976869

Group type: EXPERIMENTAL
Intervention: Ralimetinib (100 mg/12 h) with chemoradiotherapy (RT 60 Gy in 30 fractions and TMZ 75 mg/m2/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ralimetinib (200 mg/12 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ralimetinib (300 mg/12 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard concurrent RT and TMZ
Number of subjects: 18
Study: 32086341

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1548
Study: 35847230

Group type: EXPERIMENTAL
Intervention: CarFreeMe TI program (six-week group-based support and education program)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard information related to transport options available (control)
Number of subjects: 20
Study: 34336152

Group type: EXPERIMENTAL
Intervention: Rapamycin (RAPA)
Number of subjects: 316
Study: 34620739

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection into the flexor digitorum brevis and quadratus plantae
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Number of subjects: 35

Group type: COMPARATOR
Intervention: Corticosteroid injection (methylprednisolone) into the plantar fascia
Number of subjects: 35
Study: 33560244

Group type: EXPERIMENTAL
Intervention: mHealth app and chest-wearable remote exercise monitoring; participants followed exercise videos on the app and wore a chest band for 3 months.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group self-reported exercise intensity and duration; participants engaged in traditional exercise for 3 months.
Number of subjects: 101
Study: 36267745

Group type: EXPERIMENTAL
Intervention: H-VA (high-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d with amoxicillin 750 mg q.i.d for 7 days
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: L-VA (low-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d plus amoxicillin 500 mg q.i.d for 7 days
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: VAC (amoxicillin combined with VPZ and clarithromycin): VPZ 20 mg b.i.d plus amoxicillin 750 mg plus clarithromycin 500 mg for 7 days
Number of subjects: 230
Study: 32529596

Group type: EXPERIMENTAL
Intervention: Nordic Walking
Number of subjects: 32

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 32
Study: 33608936

Group type: EXPERIMENTAL
Intervention: Vincristine (VCR)
Number of subjects: 59
Study: 35728557

Group type: EXPERIMENTAL
Intervention: Water cleaning method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothbrush cleaning method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotton swab cleaning method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EnClean® brush cleaning method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncleaned control
Number of subjects: 0
Study: 33493193

Group type: EXPERIMENTAL
Intervention: Pregnancy-induced hypertension
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: One time ANC visits
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Premature rupture of membrane
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Birth interval less than two years
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Anemia during current pregnancy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: No dietary supplementation during current pregnancy
Number of subjects: 516
Study: 35406052

Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 137
Study: 32931045

Group type: EXPERIMENTAL
Intervention: Exemplary hygiene practices (Condition 2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Poor hygiene practices (Condition 1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control condition (Condition 3)
Number of subjects: 65
Study: 36157391

Group type: EXPERIMENTAL
Intervention: VFR with low frequency (35 Hz)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: VFR with high frequency (67 Hz)
Number of subjects: 16
Study: 35338131

Group type: EXPERIMENTAL
Intervention: PvCS formulated in Montanide ISA‐51 adjuvant
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (adjuvant alone)
Number of subjects: 35
Study: 33535338

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP) for 6 months
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 358
Study: 33164941

Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33920971

Group type: EXPERIMENTAL
Intervention: Multi-component intervention focusing on reducing sedentariness
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Multi-component intervention focusing on increasing physical activity
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 263
Study: 33579317

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 22
Study: 33103389

Group type: EXPERIMENTAL
Intervention: Mozart music
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethnic music
Number of subjects: 9

Group type: COMPARATOR
Intervention: No music
Number of subjects: 9
Study: 33870833

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study: 35686460

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg) + Acute Intermittent Hypoxia (AIH; FIO2=0.10)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo + Acute Intermittent Hypoxia (AIH; FIO2=0.10)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg) + SHAM (FIO2=0.21)
Number of subjects: 12
Study: 33582533

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet therapy (LGIT) for 3 months along with ongoing antiepileptic drugs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet therapy (LGIT)
Number of subjects: 40
Study: 36279581

Group type: EXPERIMENTAL
Intervention: Early division group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional division group
Number of subjects: 70
Study: 34329580

Group type: EXPERIMENTAL
Intervention: Current approaches to risk stratification and treatment of polycythaemia vera
Number of subjects: 0
Study: 34076644

Group type: EXPERIMENTAL
Intervention: Mineralized plasmatic matrix grafts (MPM)
Number of subjects: 26
Study: 33822986

Group type: EXPERIMENTAL
Intervention: Radiotherapy to both prostate and metastatic regions
Number of subjects: 35
Study: 34196980

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive use
Number of subjects: 1932
Study: 33509113

Group type: EXPERIMENTAL
Intervention: Everyday Cognition Training Programme
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conventional Cognitive Training Programme
Number of subjects: 237
Study: 35076698

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) treatment
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Control (no CCP treatment)
Number of subjects: 2287
Study: 33219473

Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diagnostic-driven therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ANC < 0.1 × 10^9/L
Number of subjects: 100

Group type: COMPARATOR
Intervention: ANC ≥ 0.1 × 10^9/L
Number of subjects: 100
Study: 32890282

Group type: EXPERIMENTAL
Intervention: Visit-to-visit SBP variability (measured as coefficient of variation)
Number of subjects: 28790

Group type: EXPERIMENTAL
Intervention: On-treatment mean SBP
Number of subjects: 28790

Group type: EXPERIMENTAL
Intervention: Combined use of SBP-CV and mean SBP quintiles
Number of subjects: 28790

Group type: EXPERIMENTAL
Intervention: Initial micro or macroalbuminuria
Number of subjects: 28790
Study: 35487708

Group type: EXPERIMENTAL
Intervention: Medicines at Transition Intervention (MaTI)
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2100
Study: 33892217

Group type: EXPERIMENTAL
Intervention: ACT-guided treatment
Number of subjects: 530
Study: 35410433

Group type: EXPERIMENTAL
Intervention: Lumbrokinase plus aspirin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 220
Study: 34233378

Group type: EXPERIMENTAL
Intervention: 595-nm pulsed dye laser (PDL) treatment with oxymetazoline cream
Number of subjects: 34

Group type: COMPARATOR
Intervention: oxymetazoline cream alone
Number of subjects: 34
Study: 35762297

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carboxytherapy
Number of subjects: 30
Study: 32247586

Group type: EXPERIMENTAL
Intervention: Robotic pancreaticoduodenectomy (RPD)
Number of subjects: 103
Study: 35429351

Group type: EXPERIMENTAL
Intervention: Laser+SE-FS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acid-etch+SE-FS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser+Acid-etch+SE-FS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical preparation+SE-FS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SE-FS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acid-etch+Bonding+Conventional fissure sealant
Number of subjects: 60
Study: 33478433

Group type: EXPERIMENTAL
Intervention: OB Nest prenatal care (telemedicine-enhanced with reduced in-person visits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional prenatal care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OB Nest prenatal care
Number of subjects: 0
Study: 32576228

Group type: EXPERIMENTAL
Intervention: 250 mL/day soy milk plus routine treatments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine treatments only
Number of subjects: 30
Study: 33021402

Group type: EXPERIMENTAL
Intervention: After-Action Reviews (AARs)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-After-Action Reviews (non-AAR)
Number of subjects: 84
Study: 33249759

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 206
Study: 35397292

Group type: EXPERIMENTAL
Intervention: Duavee® (bazedoxifene + conjugated estrogen)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34083233

Group type: EXPERIMENTAL
Intervention: ctDNA-positive patients (n=140)
Number of subjects: 1017

Group type: COMPARATOR
Intervention: ctDNA-negative patients (n=877)
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: ctDNA as an independent prognostic marker for DFS
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: ctDNA as an independent prognostic marker for OS
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: ctDNA in patients treated for 3 months with T4 and/or N2 tumors
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: ctDNA in patients treated for 6 months with T1-3/N1 tumors
Number of subjects: 1017
Study: 34426075

Group type: EXPERIMENTAL
Intervention: Pigtail catheter group
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1375
Study: 32540624

Group type: EXPERIMENTAL
Intervention: Handlebars (control plus two red rear‐facing lights on each handlebar)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Helmet (control plus one red rear‐facing light on the helmet)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Leg Retro‐reflectors (control plus retro‐reflective strips positioned on the knees and ankles)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (red rear‐facing light and reflector)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Helmet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Handlebars
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Leg Retro‐reflectors
Number of subjects: 14
Study: 34042566

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (20 Gy in five fractions or 30 Gy in 10 fractions)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care (stent insertion alone)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220
Study: 32487334

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Grommet placement with dexamethasone delivery followed by dexamethasone ear drop application
Number of subjects: 56
Study: 36449421

Group type: EXPERIMENTAL
Intervention: Enhanced Focused Concentration and Attention Learning (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced conventional driver's education (control)
Number of subjects: 0
Study: 33095038

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32530412

Group type: EXPERIMENTAL
Intervention: Intensive treatment with an early warning system for serum creatinine rise, immediate specialist consultation, and issuance of a patient kidney passport.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intensive treatment (intervention group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 26
Study: 35551757

Group type: EXPERIMENTAL
Intervention: High fat diet (HF; 36% calories from saturated fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: T cell deletion (CD247 KO) with high fat diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control normal fat diet (NF; 7.2% calories from fat)
Number of subjects: 12
Study: 32100212

Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 360

Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 360
Study: 33496535

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Myofascial manipulation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 32370822

Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Surgical liver resection
Number of subjects: 59
Study: 35466595

Group type: EXPERIMENTAL
Intervention: 6-week multicomponent positive psychology intervention (MPPI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 33476107

Group type: EXPERIMENTAL
Intervention: Affective and Sensory Psychotherapy Protocol (ASPP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 32108398

Group type: EXPERIMENTAL
Intervention: Standard image analysis
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subregional analysis (0-30% short T2 *)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subregional analysis (30-60% short T2 *)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subregional analysis (60-100% short T2 *)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Biexponential fitting
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Test-retest reliability assessment
Number of subjects: 65
Study: 36201383

Group type: EXPERIMENTAL
Intervention: Feedback group (received sleep feedback messages)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (did not receive sleep feedback messages)
Number of subjects: 31
Study: 34151444

Group type: EXPERIMENTAL
Intervention: COOL Passport mobile healthcare application (n=49)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Health Promotion Cloud system with game-based interactive platforms and COOL Passport (n=47)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard-care control group (n=47)
Number of subjects: 143
Study: 36356999

Group type: EXPERIMENTAL
Intervention: Standard care treatment for low-risk BCCs.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Non-treatment arm with close monitoring using multispectral dermoscopy, reflectance confocal microscopy, and high-definition optical coherence tomography.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Non-treatment arm (control).
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Treatment arm.
Number of subjects: 272
Study: 33555548

Group type: EXPERIMENTAL
Intervention: Genetically predicted serum creatinine (sCr) in European population
Number of subjects: 84894

Group type: EXPERIMENTAL
Intervention: Genetically predicted serum creatinine (sCr) in East Asian population
Number of subjects: 84894
Study: 32149427

Group type: EXPERIMENTAL
Intervention: VY‐AADC01 administration
Number of subjects: 13

Group type: COMPARATOR
Intervention: Levopoda infusions pre-VY‐AADC01
Number of subjects: 13

Group type: COMPARATOR
Intervention: Levopoda infusions post-VY‐AADC01
Number of subjects: 13
Study: 32735112

Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE) 65 g
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bicarbonate (BIC) 300 mg·kg‐1 body weight
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE) + Bicarbonate (BIC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control drink (CON)
Number of subjects: 9
Study: 32692763

Group type: EXPERIMENTAL
Intervention: Inhibition of circ-PLXNA1
Number of subjects: 0

Group type: COMPARATOR
Intervention: si-CTNNB1 transfection
Number of subjects: 0
Study: 35292258

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 159

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 159
Study: 35429955

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g) administered 1 hour before and 6 hours after ERCP
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo (normal saline) administered 1 hour before and 6 hours after ERCP
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g) in high risk patients
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g)
Number of subjects: 270
Study: 34081012

Group type: EXPERIMENTAL
Intervention: Platform + Coach
Number of subjects: 828

Group type: COMPARATOR
Intervention: Platform Only
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Platform Only or Platform + Coach
Number of subjects: 828
Study: 35610606

Group type: EXPERIMENTAL
Intervention: Nomogram based on independent prognostic factors (surgery, AJCC stage, laterality, tumor size, histological grade)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1375